NEW
YORK, Feb. 16, 2024 /PRNewswire/ -- Rowley Law
PLLC is investigating potential securities law violations by
Kinnate Biopharma Inc. (NASDAQ: KNTE) and its board of directors
concerning the proposed acquisition of the company by XOMA
Corporation. Stockholders will receive between $2.3352 and $2.5879, as well as one contingent value right,
for each share of Kinnate Biopharma stock that they hold. The
transaction is expected to close in the first half of 2024.
If you are a stockholder of Kinnate Biopharma Inc. and are
interested in obtaining additional information regarding this
investigation, please visit us
at: http://www.rowleylawpllc.com/investigation/knte/. You may
also contact Shane Rowley, Esq. at
Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at
info@rowleylawpllc.com, or by telephone at 914-400-1920 or
844-400-4643 (toll-free).
Rowley Law PLLC represents shareholders nationwide in class
actions and derivative lawsuits in complex corporate litigation.
For more information about the firm and its attorneys, please visit
http://www.rowleylawpllc.com.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
View original
content:https://www.prnewswire.com/news-releases/alert-rowley-law-pllc-is-investigating-proposed-acquisition-of-kinnate-biopharma-inc-302064364.html
SOURCE Rowley Law PLLC